AVANOVA1 - Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer

Trial Profile

AVANOVA1 - Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Niraparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AVANOVA; AVANOVA1; AVANOVA2
  • Most Recent Events

    • 09 Aug 2017 According to a TESARO Inc. media release, data from this trial are expected to be presented at the European Society for Medical Oncology (ESMO) Congress 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Apr 2017 Planned number of patients changed from 147 to 108.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top